Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
On Wednesday, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Livsayis (cemdisiran) for generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) antibodies, the predominant form of the disease. Livsayis stands as the first and only approved small interfering RNA (siRNA) therapy for gMG. It also represents…
On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval to Regeneron Pharmaceuticals Inc. for Livsayis, a four-times-yearly gene therapy targeting generalized myasthenia gravis (gMG) in adults with positive anti-acetylcholine receptor (AChR) antibodies. This marks the first and only FDA-approved small interfering RNA (siRNA) therapy for gMG, and the only treatment currently administered subcutaneously every four weeks.
The innovative treatment targets complement component factor 5 (C5) to reduce circulating C5 protein levels and limit terminal complement activation, a primary cause of the disease. The FDA's approval was based on data from the Phase 3 NIMBLE trial, showing Livsayis achieved a 2.3-point improvement in the MG-ADL score at 24 weeks compared to a 2.2-point improvement for placebo.
Additionally, 76.6% of Livsayis patients experienced at least a 3-point improvement in the MG-ADL score at 24 weeks, compared to 44.1% of placebo recipients. Livsayis also demonstrated significant gains in muscle function, with a 2.8-point placebo-adjusted benefit in the QMG scale at 24 weeks, compared to 1.5 points for placebo.
The drug provided rapid symptom relief, with patients experiencing a clinically meaningful 2.5-point MG-ADL improvement within two weeks, which persisted throughout the 24-week study period without signs of diminishing efficacy.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.